Last reviewed · How we verify
NCT06867978: PRECISION
Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis.
Phase 1 trial testing cCeLL In vivo in Frozen Sections in 100 participants. Not yet recruiting.
30 June 2026
Quick facts
| Lead sponsor | VPIX Medical |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 1 June 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- cCeLL In vivo
- Indocyanine Green (INDOCYANINE GREEN) — full drug profile →
Conditions studied
- Frozen Sections — all drugs for Frozen Sections →
- Indocyanine Green — all drugs for Indocyanine Green →
- Brain Tumor — all drugs for Brain Tumor →
Sponsor
VPIX Medical
Who can join
18 and older, any sex, with Frozen Sections or Indocyanine Green. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to demonstrate the non-inferiority of cCeLL compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, which is then read and analyzed by trained-professional for intraoperative diagnosis. The comparison will be held by the device with the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06867978
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cCeLL In vivo
Trials testing the same drug.
- NCT07254845 — A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HIS · Phase 1 · not yet recruiting
Other VPIX Medical trials
Trials by the same sponsor.
- NCT07254845 — A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HIS · Phase 1 · not yet recruiting
- NCT06098248 — Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06867978 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VPIX Medical
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06867978.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing